Zacks Investment Research
18 Aug 2026, 17:46 UTC · 1h ago
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
18 Aug 2026, 17:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Medpace (MEDP) is currently recommended as a top growth stock with a favorable Zacks Growth Style Score and a top Zacks Rank. — A high-conviction analyst recommendation for a specific small-to-mid-cap stock typically drives short-term buying pressure.
+0.40Medpace's EPS is projected to grow by 14.6% this year, exceeding the industry average of 13.7%. — Outperforming industry peers in earnings growth is a fundamental catalyst for price appreciation.
+0.30Medpace has maintained a historical EPS growth rate of 31.2%. — Strong historical growth provides a baseline of confidence in the company's business model, though it is less impactful than future projections.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Recommended as a great growth pick with a top Zacks Rank and projected EPS growth that beats the industry average.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
